サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788259

ペプチド薬物複合体の世界市場

Peptide Drug Conjugates

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
ペプチド薬物複合体の世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ペプチド薬物複合体の世界市場は2030年までに95億米ドルに達する見込み

2024年に36億米ドルと推定されるペプチド薬物複合体の世界市場は、2024年から2030年にかけてCAGR 17.5%で成長し、2030年には95億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPluvictoは、CAGR 16.1%を記録し、分析期間終了時には38億米ドルに達すると予測されています。オクトレオスキャン（OctreoScan）分野の成長率は、分析期間のCAGRで18.3％と推定されます。

米国市場は9億8,600万米ドルと推定、中国はCAGR 22.9％で成長予測

米国のペプチド薬物複合体市場は、2024年に9億8,600万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは22.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.2%と15.7%と予測されています。欧州では、ドイツがCAGR約13.9%で成長すると予測されています。

世界のペプチド薬物複合体市場- 主要動向と促進要因まとめ

ペプチド薬物複合体とは何か？

ペプチド薬物複合体（PDC）は、ペプチドの治療特性と薬剤分子の標的デリバリー能力を組み合わせたバイオ医薬品のクラス別です。これらのコンジュゲートは、特定のレセプターやバイオマーカーに対して高い特異性を持つ生理活性ペプチドを、通常安定な化学結合を介して細胞毒性あるいは治療薬と結合させることによって形成されます。PDCの主な目的は、腫瘍や感染組織などの作用部位にペプチドを介して薬剤を直接送達することで、副作用を最小限に抑えながら治療効果を高めることです。この標的デリバリー機構により、薬物は健康な組織を温存しながら病変細胞に特異的に作用し、全身毒性を軽減して治療効果を高めることができます。

PDCにおけるペプチドの使用は、特定の細胞レセプターに選択的に結合する能力によって推進され、標的療法の理想的な候補となります。例えば、がん治療では、特定の受容体や酵素などのバイオマーカーを過剰発現している腫瘍細胞に直接細胞毒性薬を送達するようにPDCを設計することができます。これらのバイオマーカーを認識するペプチドを利用することで、PDCは化学療法剤や免疫調節剤などの強力なドラッグデリバリーを可能にし、薬剤の治療指数を高める。PDCは、腫瘍学、自己免疫疾患、感染症などの分野で有望視されており、従来の全身薬物療法に代わる、より効果的で毒性の低い治療法を提供しています。

なぜペプチド薬物複合体市場は拡大しているのか？

ペプチド薬物複合体市場は、がんやその他の慢性疾患の有病率の増加、標的治療に対する需要の高まり、ペプチドベースの創薬の進歩など、いくつかの要因によって急速な成長を遂げています。市場拡大の最も大きな促進要因のひとつは、世界のがん罹患率の上昇です。化学療法や放射線療法といった従来の治療法はしばしば深刻な副作用を引き起こすため、より精密で全身への影響が少ない治療法に対する需要が高まっています。PDCはがん細胞を選択的に標的とする可能性があり、従来の化学療法に比べて副作用が少なく、より効果的な治療を可能にします。

個別化医療へのシフトも、ペプチド薬物複合体市場の成長を後押しする重要な要因です。個別化医療とは、患者の遺伝的体質や疾患の特徴に基づいて、個々の患者に合わせた治療を行うことです。ペプチドは高い特異性とユニークなバイオマーカーを標的にする能力を持ち、個別化治療に最適です。特定のがん細胞マーカーやレセプターを認識し結合できるペプチドを用いることで、PDCは個々の患者に合わせたより効果的な治療戦略を可能にします。このような個別化された標的療法への注目は、今後もペプチド薬物複合体への関心と投資を促進すると思われます。

ペプチドベースの創薬技術やコンジュゲーション技術の進歩もPDC市場の成長に寄与しています。ペプチド合成とコンジュゲーション技術の研究が進化し続けるにつれて、標的に対して高い親和性を持つペプチドの開発がより容易になり、コスト効率も向上しています。さらに、ペプチドと薬物分子をつなぐリンカー化学の改良により、PDCの安定性、有効性、安全性プロファイルが向上しています。これらの進歩により、幅広い疾患に使用可能な新規PDC療法の開発が可能になり、ペプチド薬物複合体の応用可能性がさらに広がっています。

ペプチド薬物複合体の将来を形作る主要動向は？

ペプチド薬物複合体の将来は、ペプチド合成やコンジュゲーション技術の進歩、併用療法の台頭、非がん領域におけるPDCの適用拡大など、いくつかの重要な動向によって形作られています。重要な動向の一つは、ペプチド合成とコンジュゲーション技術の継続的な向上です。固相ペプチド合成（SPPS）と自動コンジュゲーション法の開発により、高品質なペプチドの生産と、より洗練されたPDCの開発が可能となっています。これらの進歩はペプチド薬物複合体のスケーラビリティにも寄与しており、臨床使用に向けてより効率的に製造できるようになっています。

もう一つの重要な動向は、併用療法におけるPDCの使用の増加です。ペプチド薬物複合体を免疫チェックポイント阻害剤、モノクローナル抗体、従来の化学療法などの他の治療法と併用する併用療法が勢いを増しています。これらの併用療法は、複数の経路を標的としたり、がんと闘う免疫系の能力を高めたりすることによって、全体的な治療成績を向上させるようにデザインされています。PDCと他の治療法の併用による相乗効果は、特に治療困難ながんにおいて、奏効率の改善、抵抗性の低下、長期予後の改善につながる可能性があります。

がん以外の疾患におけるPDCの応用拡大も、この市場の将来を形成しています。PDCはこれまで主にがん領域に焦点を当ててきたが、自己免疫疾患、感染症、さらには神経疾患の治療にも使用することへの関心が高まっています。ペプチド薬物複合体が、より制御された方法で疾患部位を特異的に標的とする能力を持つことは、高度に標的化された治療的介入を必要とする疾患の治療に新たな道を開くものです。PDCの広範な応用に関する調査が進むにつれて、世界産業アナリストは、これらの治療法がより多様な臨床適応症で使用されるようになることを期待しています。

ペプチド薬物複合体市場の成長促進要因は？

ペプチド薬物複合体市場の成長は、標的治療に対するニーズの高まり、ペプチドベースの創薬の進歩、効果的ながん治療に対する世界の需要の高まりなど、いくつかの重要な要因によってもたらされます。最も重要な促進要因のひとつは、世界のがん罹患率の増加であり、がん細胞をより選択的に標的とする治療法へのシフトを促しています。従来の化学療法は、有効ではあるが、特異性がないため、しばしば重大な副作用を引き起こします。ペプチド薬物複合体は、薬剤を腫瘍部位に直接送達することにより、副作用が少なく、より効果的な治療の可能性を提供し、がんとの闘いにおいて非常に魅力的なものとなっています。

ペプチド合成技術や薬物結合技術の進歩も市場を牽引しています。より効率的でコスト効率の高い製造法の開発など、ペプチド合成技術の向上により、標的バイオマーカーに対する特異性と親和性の高いペプチドの作製が容易になりました。さらに、薬剤とペプチドをより効果的に結合させる新規リンカー技術の開発により、ペプチド薬物複合体の安定性と有効性が向上しています。これらの技術革新により、様々な臨床応用に適した、より強力で安全な治療薬の創製が可能になりつつあります。

個別化医療と精密腫瘍学への注目の高まりも大きな推進力です。個別化されたがん治療の需要が高まるにつれ、個人の遺伝子プロファイルや腫瘍マーカーに基づいて治療を調整する能力が極めて重要になっています。ペプチド薬物複合体は、高い特異性とユニークな分子マーカーを標的とする能力を持ち、この種の治療アプローチに理想的に適しています。より的を絞った個別化治療を提供することで、PDCはがん治療の有効性を向上させ、副作用を軽減し、市場の成長をさらに促進すると期待されています。新たなペプチドターゲットや薬剤の組み合わせの研究が進むにつれて、PDCの潜在的な用途は拡大し、この革新的な市場のさらなる成長を促進すると予想されます。

セグメント

製品タイプ（Pluvicto、OctreoScan、Lutathera、Illuccix、その他の製品タイプ）;エンドユーザー（治療エンドユーザー、診断エンドユーザー）

調査対象企業の例

  • Angiochem Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics
  • Coherent Biopharma
  • Curium US LLC
  • Cybrexa Therapeutics
  • E. Merck KG
  • Ellipses Pharma
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals
  • Italfarmaco SpA
  • Novartis AG
  • Oncopeptides AB
  • PeptiDream Inc.
  • ProteinQure Inc.
  • Samsung Biologics
  • SignalChem Lifesciences
  • Soricimed Biopharma
  • Telix Pharmaceuticals Limited
  • Theratechnologies Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32518

Global Peptide Drug Conjugates Market to Reach US$9.5 Billion by 2030

The global market for Peptide Drug Conjugates estimated at US$3.6 Billion in the year 2024, is expected to reach US$9.5 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Pluvicto, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the OctreoScan segment is estimated at 18.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$986.0 Million While China is Forecast to Grow at 22.9% CAGR

The Peptide Drug Conjugates market in the U.S. is estimated at US$986.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 22.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global Peptide Drug Conjugates Market - Key Trends & Drivers Summarized

What Are Peptide Drug Conjugates and How Do They Work?

Peptide drug conjugates (PDCs) are a class of biopharmaceuticals that combine the therapeutic properties of peptides with the targeted delivery capabilities of drug molecules. These conjugates are formed by linking a bioactive peptide, which has high specificity for a particular receptor or biomarker, to a cytotoxic or therapeutic drug, typically via a stable chemical bond. The primary goal of PDCs is to enhance the effectiveness of treatments while minimizing side effects by ensuring that the drug is delivered directly to the site of action, such as a tumor or an infected tissue, via the peptide. This targeted delivery mechanism allows the drug to act specifically on the diseased cells while sparing healthy tissues, reducing systemic toxicity and enhancing therapeutic efficacy.

The use of peptides in PDCs is driven by their ability to selectively bind to specific cellular receptors, making them ideal candidates for targeted therapies. For instance, in cancer treatment, PDCs can be designed to deliver cytotoxic drugs directly to tumor cells that overexpress specific biomarkers, such as certain receptors or enzymes. By utilizing peptides that recognize these biomarkers, PDCs enable the targeted delivery of potent drugs, such as chemotherapy agents or immune modulators, thereby increasing the therapeutic index of the drug. PDCs have shown promise in oncology, autoimmune diseases, and infectious diseases, providing more effective and less toxic alternatives to traditional systemic drug therapies.

Why Is the Peptide Drug Conjugates Market Expanding?

The peptide drug conjugates market is experiencing rapid growth driven by several factors, including the increasing prevalence of cancer and other chronic diseases, the growing demand for targeted therapies, and advancements in peptide-based drug discovery. One of the most significant drivers of the market's expansion is the rising global burden of cancer. As traditional treatments such as chemotherapy and radiation therapy often cause severe side effects, there is a growing demand for therapies that are more precise and have fewer systemic effects. PDCs offer the potential to selectively target cancer cells, allowing for more effective treatment with fewer side effects compared to conventional chemotherapies.

The shift toward personalized medicine is another key factor fueling the growth of the peptide drug conjugates market. Personalized medicine involves tailoring treatments to individual patients based on their genetic makeup and the specific characteristics of their disease. Peptides, with their high specificity and ability to target unique biomarkers, are a perfect fit for personalized therapies. By using peptides that can recognize and bind to specific cancer cell markers or receptors, PDCs enable more effective treatment strategies tailored to the individual patient. This focus on personalized, targeted therapies is likely to continue driving interest and investment in peptide drug conjugates.

Advancements in peptide-based drug discovery and conjugation technologies are also contributing to the growth of the PDC market. As research in peptide synthesis and conjugation techniques continues to evolve, it is becoming easier and more cost-effective to develop peptides with high affinity for their targets. Additionally, improvements in linker chemistry, which connects the peptide to the drug molecule, have enhanced the stability, efficacy, and safety profile of PDCs. These advancements allow for the development of novel PDC therapies that can be used in a wide range of diseases, further expanding the potential applications of peptide drug conjugates.

What Key Trends Are Shaping the Future of Peptide Drug Conjugates?

The future of peptide drug conjugates is being shaped by several important trends, including advancements in peptide synthesis and conjugation technologies, the rise of combination therapies, and the expanding application of PDCs in non-oncology indications. One significant trend is the continued improvement in peptide synthesis and conjugation techniques. Advances in solid-phase peptide synthesis (SPPS) and automated conjugation methods are enabling the production of high-quality peptides and the development of more sophisticated PDCs. These advancements are also contributing to the scalability of peptide drug conjugates, allowing them to be manufactured more efficiently for clinical use.

Another key trend is the increasing use of PDCs in combination therapies. Combination therapies, where peptide drug conjugates are used alongside other treatment modalities such as immune checkpoint inhibitors, monoclonal antibodies, or conventional chemotherapy, are gaining momentum. These combinations are designed to improve the overall therapeutic outcome by targeting multiple pathways or enhancing the immune system’s ability to fight cancer. The synergistic effects of combining PDCs with other therapies could lead to improved response rates, reduced resistance, and better long-term outcomes, particularly in hard-to-treat cancers.

The expanding application of PDCs in non-oncology diseases is also shaping the future of this market. While PDCs have been primarily focused on oncology, there is growing interest in using them for the treatment of autoimmune diseases, infectious diseases, and even neurological disorders. The ability of peptide drug conjugates to specifically target disease sites in a more controlled manner opens new avenues for treating diseases that require highly targeted therapeutic interventions. As research into the broad applications of PDCs continues, we can expect to see these therapies being used in a wider variety of clinical indications.

What Are the Key Drivers of Growth in the Peptide Drug Conjugates Market?

The growth in the peptide drug conjugates market is driven by several key factors, including the increasing need for targeted therapies, advancements in peptide-based drug discovery, and the growing global demand for effective cancer treatments. One of the most important drivers is the increasing prevalence of cancer worldwide, which is prompting a shift toward therapies that can target cancer cells more selectively. Traditional chemotherapies, while effective, often cause significant side effects due to their lack of specificity. Peptide drug conjugates, by delivering drugs directly to the tumor site, offer the potential for more effective treatment with fewer side effects, making them highly attractive in the fight against cancer.

Advancements in peptide synthesis and drug conjugation technologies are also driving the market. Improved peptide synthesis techniques, including the development of more efficient and cost-effective production methods, have made it easier to create peptides with high specificity and affinity for target biomarkers. Additionally, the development of novel linker technologies that can more effectively conjugate drugs to peptides has enhanced the stability and efficacy of peptide drug conjugates. These innovations are enabling the creation of more potent and safe therapies that are suitable for a variety of clinical applications.

The increasing focus on personalized medicine and precision oncology is another major driver. As the demand for personalized cancer treatments rises, the ability to tailor therapies based on individual genetic profiles and tumor markers has become crucial. Peptide drug conjugates, with their high specificity and ability to target unique molecular markers, are ideally suited for this type of treatment approach. By providing more targeted and personalized therapies, PDCs are expected to improve the efficacy of cancer treatments and reduce adverse effects, further fueling the growth of the market. As research continues to uncover new peptide targets and drug combinations, the potential applications for peptide drug conjugates are expected to expand, driving further growth in this innovative market.

SCOPE OF STUDY:

The report analyzes the Peptide Drug Conjugates market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Pluvicto, OctreoScan, Lutathera, Illuccix, Other Product Types); End-Use (Therapeutic End-Use, Diagnostic End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Angiochem Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics
  • Coherent Biopharma
  • Curium US LLC
  • Cybrexa Therapeutics
  • E. Merck KG
  • Ellipses Pharma
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals
  • Italfarmaco SpA
  • Novartis AG
  • Oncopeptides AB
  • PeptiDream Inc.
  • ProteinQure Inc.
  • Samsung Biologics
  • SignalChem Lifesciences
  • Soricimed Biopharma
  • Telix Pharmaceuticals Limited
  • Theratechnologies Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide Drug Conjugates - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Oncology Incidence Globally Spurs Demand for Targeted Peptide Drug Conjugates
    • Expanding Clinical Pipeline Throws the Spotlight on Late-Stage Candidates and Near-Term Commercialization
    • Precision Medicine Advancements Strengthen Business Case for Peptide-Based Therapeutics
    • Expanding Use of Peptide Drug Conjugates in Rare Diseases Expands Addressable Market Opportunity
    • Integration of AI and Machine Learning in Drug Design Drives Innovation in Peptide Conjugate Development
    • Biopharmaceutical Outsourcing Trends Propel Growth in CDMO Services for Peptide Conjugation
    • High Selectivity and Targeting Capabilities of Peptides Accelerate Demand in Precision Oncology
    • Government Funding for Cancer Research and Rare Disease Therapeutics Spurs Pipeline Expansion
    • Advances in Solid-Phase Peptide Synthesis Expand Manufacturing Scalability and Market Reach
    • Growing Focus on Antibody Alternatives Throws the Spotlight on Peptide Conjugates as Scalable Solutions
    • Emergence of Multifunctional Conjugates Expands Product Innovation Opportunities in Oncology and Beyond
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide Drug Conjugates Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide Drug Conjugates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pluvicto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pluvicto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pluvicto by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for OctreoScan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for OctreoScan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for OctreoScan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lutathera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lutathera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Lutathera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Illuccix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Illuccix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Illuccix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapeutic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Therapeutic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Therapeutic End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Peptide Drug Conjugates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Peptide Drug Conjugates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Peptide Drug Conjugates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Peptide Drug Conjugates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION